Brain Protein FSTL1 Reverses Obesity by Restoring Insulin Sensitivity in Mice
Scientists discover a hypothalamic protein that fights diet-induced obesity by enhancing insulin signaling in hunger-regulating neurons.
Summary
Researchers at Chongqing Medical University identified Follistatin-like 1 (FSTL1) as a critical brain protein that counteracts diet-induced obesity. Normally enriched in the hypothalamic arcuate nucleus, FSTL1 levels drop in obese and diabetic mice. When deleted specifically from AgRP neurons — the brain's hunger-promoting cells — mice ate more, burned less energy, and became insulin resistant. Conversely, boosting FSTL1 in these neurons reversed those effects. Remarkably, delivering FSTL1 via nasal spray promoted weight loss and improved insulin sensitivity in obese mice. The protein works by binding to Akt, a key insulin signaling molecule, preventing a transcription factor called FoxO1 from entering the nucleus and driving metabolic dysfunction. These findings position hypothalamic FSTL1 as a promising therapeutic target for obesity.
Detailed Summary
Obesity and insulin resistance remain among the most pressing metabolic health challenges, and existing treatments often address peripheral tissues while overlooking the brain's central role in energy regulation. This study highlights how a signaling molecule in the hypothalamus could be key to reversing diet-induced obesity.
Researchers focused on Follistatin-like 1 (FSTL1), a protein known for its roles in peripheral energy metabolism but whose function in the brain had been unexplored. They found FSTL1 is highly concentrated in the hypothalamus — particularly in the arcuate nucleus (ARC) — a brain region that governs appetite and energy expenditure. Critically, FSTL1 expression was reduced in both diet-induced obese (DIO) and genetically diabetic (db/db) mice, suggesting it plays a protective metabolic role.
Using genetic tools to selectively delete or overexpress Fstl1 in AgRP neurons (which normally promote hunger and suppress energy use), the team showed that loss of FSTL1 worsened obesity-related outcomes — increased food intake, reduced energy expenditure, and impaired insulin sensitivity. Overexpression produced the opposite, beneficial effects. These findings confirm that hypothalamic FSTL1 in AgRP neurons is essential for maintaining metabolic balance.
Mechanistically, FSTL1 physically interacts with Akt, a central node in insulin signaling, to prevent FoxO1 from translocating into the nucleus — a process that normally drives metabolic dysfunction when unchecked. Most translationally exciting, intranasal delivery of FSTL1 protein to DIO mice triggered measurable weight loss and restored insulin sensitivity, demonstrating a feasible non-invasive delivery route.
While compelling, these results are based entirely on mouse models, and whether FSTL1 behaves similarly in human hypothalami remains to be established. Nonetheless, this research opens a new pharmacological avenue targeting central insulin sensitization for obesity treatment.
Key Findings
- FSTL1 is enriched in hypothalamic arcuate nucleus and is reduced in obese and diabetic mice.
- Deleting FSTL1 in AgRP neurons increased food intake, reduced energy expenditure, and worsened insulin resistance.
- Overexpressing FSTL1 in AgRP neurons reversed diet-induced obesity phenotypes in mice.
- Intranasal FSTL1 delivery promoted weight loss and improved insulin sensitivity non-invasively.
- FSTL1 acts by binding Akt to block FoxO1 nuclear translocation, enhancing insulin signaling.
Methodology
The study used diet-induced obese (DIO) and db/db mouse models with AgRP neuron-specific Fstl1 knockout and overexpression via genetic tools. Metabolic phenotyping included food intake, energy expenditure, and insulin sensitivity measurements. Intranasal protein delivery was tested as a translational intervention, and mechanistic studies examined FSTL1 interactions with Akt and FoxO1.
Study Limitations
All experiments were conducted in mouse models; human hypothalamic FSTL1 function has not yet been validated. The long-term safety and efficacy of intranasal FSTL1 delivery in humans is unknown. The study relied on the abstract alone, so full mechanistic details and statistical rigor could not be fully assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: